Fig. 1: Outcome after alloHCT for patients with CLL who have been exposed to idelalisib.

a, b Shows overall and progression-free survival with point-wise 95%-confidence intervals, respectively. c Shows the cumulative incidences of relapse and non-relapse mortality.